Format

Send to

Choose Destination
J Diabetes Complications. 2015 Nov-Dec;29(8):1272-6. doi: 10.1016/j.jdiacomp.2015.08.023. Epub 2015 Sep 3.

Gastrointestinal microbiome modulator improves glucose tolerance in overweight and obese subjects: A randomized controlled pilot trial.

Author information

1
Pennington Biomedical Research Center, Louisiana State University System, 6400, Perkins Road Baton Rouge, LA 70808, USA; School of Nutrition and Food Sciences, Louisiana State University, Baton Rouge, LA 70803, USA. Electronic address: Candida.Rebello@pbrc.edu.
2
Pennington Biomedical Research Center, Louisiana State University System, 6400, Perkins Road Baton Rouge, LA 70808, USA. Electronic address: Jeff.Burton@pbrc.edu.
3
MicroBiome Therapeutics LLC, 1316 Jefferson Ave., New Orleans, LA 70115, USA. Electronic address: mheiman@mbiome.com.
4
Pennington Biomedical Research Center, Louisiana State University System, 6400, Perkins Road Baton Rouge, LA 70808, USA. Electronic address: Frank.Greenway@pbrc.edu.

Abstract

OBJECTIVE:

The objective of this study was to examine the effects of a gastrointestinal microbiome modulator (GIMM) containing inulin, β-glucan, blueberry anthocyanins, and blueberry polyphenols on metabolic parameters, fecal markers of gut microbiota, and satiety.

DESIGN AND METHODS:

Thirty overweight or obese individuals aged 18 to 70years, were enrolled in a randomized controlled trial. Participants consumed the test product or placebo daily for four weeks. Stool samples were collected and blood was drawn at baseline and week four for assessments of gut microbiota, satiety hormones, glucose control, and lipid measures. Subjective satiety was assessed weekly. Linear models were used to compare differences from baseline to week four.

RESULTS:

GIMM consumption improved blood glucose tolerance (p=0.008), and increased satiety (p=0.03). There were no statistically significant differences in insulin sensitivity, fecal markers of gut microbiota, plasma satiety hormones, or serum lipid concentrations between the groups. However, plasma satiety hormones and fecal short chain fatty acid concentrations increased in the test group compared to the placebo.

CONCLUSIONS:

GIMM consumption for four weeks, increases satiety, and improves glucose tolerance possibly through insulin-independent pathways.

KEYWORDS:

Blueberry; Glucose tolerance; Inulin; Microbiota; Satiety; β-Glucan

PMID:
26424589
PMCID:
PMC4656110
DOI:
10.1016/j.jdiacomp.2015.08.023
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center